FibroBiologics, Inc. Announces Reverse Stock Split and Amendment to Certificate of Incorporation

FibroBiologics, Inc. (NASDAQ: FBLG), a Houston-based life sciences company specializing in pharmaceutical preparations, has filed a Form 8-K with the U.S. Securities and Exchange Commission announcing a significant corporate action: a Reverse Stock Split and an amendment to its Amended and Restated Certificate of Incorporation. This news is of high importance to current and prospective shareholders, as such actions often have direct implications for the company’s share price and overall market capitalization.

Key Highlights from the Report

• Reverse Stock Split Implemented: The company has effected a reverse stock split, which means every outstanding share of Common Stock will be consolidated into fewer shares. The actual ratio is not specified in the report, but all fractional shares resulting from the split will be rounded up to the nearest whole share. This action affects all shareholders uniformly, preserving their percentage ownership except for minor adjustments related to fractional shares.
• Amendment to Certificate of Incorporation: A new paragraph (Paragraph D of Article FOURTH) has been added to the Certificate of Incorporation. This amendment officially documents the reverse stock split, ensures no fractional shares are issued (rounding up instead), and confirms that the number of authorized shares and the par value of Common Stock remain unchanged. The capital of the corporation is not reduced as a result of this amendment.
• Shareholder Approval: The amendment and reverse stock split were duly approved by the Board of Directors and holders of a majority of the outstanding shares, with the shareholder approval date noted as February 20, 2026.
• Adjustment of Equity Incentive Plan and Outstanding Securities: The reverse stock split will proportionately adjust the number of shares available under FibroBiologics’ equity incentive plan, as well as the exercise prices and numbers of shares underlying stock options and warrants outstanding as of the effective date of the split. This is in accordance with the terms of those securities.
• No Change to Par Value or Authorized Shares: The par value of the Common Stock (\$0.00001 per share) and the authorized number of shares remain the same. Only the number of issued and outstanding shares is affected.
• Emerging Growth Company Status: FibroBiologics is classified as an “emerging growth company” under SEC rules, which may allow the company to take advantage of certain reduced reporting requirements and extended transition periods for new financial accounting standards. However, the company has not elected to use the extended transition period.
• Trading Information: The company’s Common Stock continues to trade under the symbol FBLG on the Nasdaq Stock Market LLC.
• Corporate Details: Headquarters are at 455 E. Medical Center Blvd, Suite 300, Houston, TX, 77598. The CEO is Pete O’Heeron, and the Chief Financial Officer is Jason D. Davis.

Implications for Shareholders and Potential Price Sensitivity

• Reverse Stock Split Impact: Reverse stock splits are often implemented to increase the per-share price, possibly to meet minimum listing requirements or to enhance the company’s appeal to institutional investors. While the total value of shareholder holdings remains unchanged (except for rounding), the reduced number of shares outstanding typically results in a higher share price. However, investors should monitor trading activity, as reverse splits can signal company challenges or strategic realignment and sometimes precede increased volatility.
• Effect on Options and Warrants: Adjustments to outstanding options and warrants may affect their value and exercisability. Investors holding these instruments should closely review the new terms post-split.
• No Change to Ownership Percentage: The reverse split does not dilute shareholder ownership, except for possible rounding adjustments. However, it may affect liquidity due to fewer shares outstanding.
• Regulatory and Financial Reporting: As an emerging growth company, FibroBiologics may have lighter regulatory requirements, but has not opted for extended transition periods for financial accounting standards. This could affect future financial disclosures and reporting timelines.

Additional Corporate Disclosures

• Exhibit Filed: The full text of the Certificate of Amendment documenting the reverse stock split and related provisions is filed as Exhibit 3.1 to the Form 8-K.
• Other SEC Compliance: The Form 8-K filing includes standard disclosures indicating no written communications, no soliciting material, and no pre-commencement tender offers are associated with this action.

Conclusion

The reverse stock split and related amendment to the certificate of incorporation are major corporate actions that can influence FibroBiologics’ share price and market perception. Investors should pay close attention to post-split trading dynamics, updated option and warrant terms, and ongoing regulatory disclosures. The company’s status as an emerging growth company and its continued Nasdaq listing are also relevant for assessing future developments.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions. The author and publisher accept no liability for any actions taken based on this article.

View FibroBiologics, Inc. Historical chart here